论文部分内容阅读
目的分析通过对异位妊娠患者的大剂量米非司酮+甲氨蝶呤联合治疗异位妊娠的疗效及安全性。方法将我院符合要求的异位妊娠患者随机分为两组,即实验组,给予大剂量米非司酮+甲氨蝶呤联合治疗;对照组,给予小剂量米非司酮+甲氨蝶呤联合治疗。经2周治疗后,比较两组患者的血清-HCG、孕酮及CDFI检测来评估患者治疗成功或治疗失败。同时,观察患者治疗时是否出现恶心、呕吐、骨髓抑制、口腔溃疡、肝功肾功损害等,并进行统计。结果实验组患者治疗成功率为95.2%,明显高于对照组的75.8%,且P<0.05,差异有显著性。实验组患者不良反应发生率为11.3%,对照组患者不良反应发生率为9.7%,两组比较P>0.05,差异无显著性。结论大剂量米非司酮+甲氨蝶呤联合治疗异位妊娠的临床疗效明显高于小剂量米非司酮+甲氨蝶呤联合使用,并且没有增加副反应的发生率。
Objective To analyze the efficacy and safety of high-dose mifepristone plus methotrexate combined with ectopic pregnancy in patients with ectopic pregnancy. Methods Patients with ectopic pregnancy in our hospital were randomly divided into two groups: experimental group and high-dose mifepristone combined with methotrexate. In the control group, low-dose mifepristone combined with methotrexate Combination therapy. After two weeks of treatment, serum-HCG, progesterone, and CDFI were compared between the two groups to assess the patient’s success or failure. At the same time, to observe whether there is nausea, vomiting, myelosuppression, oral ulcer, liver function, renal function damage and so on. Results The success rate of treatment in experimental group was 95.2%, which was significantly higher than that in control group (75.8%, P <0.05). The incidence of adverse reactions in the experimental group was 11.3%, while the incidence of adverse reactions in the control group was 9.7%. There was no significant difference between the two groups (P> 0.05). Conclusion The clinical efficacy of high-dose mifepristone + methotrexate combined with ectopic pregnancy was significantly higher than that of low-dose mifepristone combined with methotrexate, and did not increase the incidence of side effects.